A lack of drugs for antibiotic-resistant Gram-negative bacteria

Nature Reviews Drug Discovery

Volumn 6, Issue 11, 2007, Pages 938-939

  Lee, Jung Hun ^a   Jeong, Seok Hoon ^b   Cha, Sun Shin ^c   Lee, Sang Hee ^a  

^a Myong Ji University   (South Korea)

^b Kosin University   (South Korea)

^c Korea Research Institute of Ships and Ocean Engineering   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN; CIPROFLOXACIN; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; MEROPENEM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; TAZOBACTAM;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ENZYME ACTIVITY; ENZYME STRUCTURE; GRAM NEGATIVE BACTERIUM; HUMAN; LETTER; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ALIGNMENT;

EID: 35748983815     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2201-c1     Document Type: Letter

References (15)

1. Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nature Rev. Drug Discov. 6, 29-40 (2007).
2. Bradley, J. S. et al. Anti-infective research and development-problems, challenges, and solutions. Lancet Infect. Dis. 7, 68-78 (2007).
3. Talbot, G. H. et al. Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect Dis. 42, 657-668 (2006).
4. Paterson, D. L & Bonomo, R. A. Extended-spectrum β-lactamases: A clinical update. Clin. Microbiol. Rev. 18, 657-686 (2005).
5. Mammeri, H. et al. AmpC β-lactamase in an Escherichia coli clinical isolate confers resistance to expanded-spectrum cephalosporins. Antimicrob. Agents Chemother. 48, 4050-4053 (2004).
6. Mammeri, H., Poirel, L. Bemer, P., Drugeon. H. & Nordmann, P. Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC β-lactamase of a Serratiamarcescens clinical isolate. Antimicrob. Agents Chemother. 48, 716-720 (2004).
7. Kim, J. Y. et al. Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C β-lactamase. Mol. Microbiol. 60, 907-916 (2006).
8. CMY-bearing plasmids among clinical Escherichia coli and Klebsiella pneumoniae isolates and emergence of cefepime-hydrolyzing CMY-19. Antimicrob. Agents Chemother. 50, 534-541 (2006).
9. Poirel, L. et al. Emergence in Klebsiella pneumoniae of a chromosome-encoded SHV β-lactamase that compromises the efficacy of imipenem. Antimicrob. Agents Chemother. 47, 755-758 (2003).
10. Lee. S. H. Jeong, S. H. & Cha, S. S. Screening for carbapenems-resistant Gram-negative bacteria. Lancet Infect Dis. 6, 682-684 (2006).
11. Lobkovsky E. et al. Evolution of an enzyme activity: crystallographic structure at 2 Å resolution of cephalosporinase from the ampC gene of Enterobacter cloacae P99 and comparison with a class A penicillinase. Proc. Natl Acad. Sci. USA 90, 11257-11261 (1993).
12. Crichlow. G. V. et al. Structure of the extended-spectrum class C β-lactamase of Enterobacter cloacae GC1, a natural mutant with a tandem tripeptide insertion. Biochemistry 38, 10256-10261 (1999).
13. Anderson A. C. The process of structure-based drug design. Chem. Biol. 10, 787-797 (2003).
14. Powers, R. A. Morandi, F. & Shoichet, B. K. Structure-based discovery of a novel, noncovalent inhibitor of AmpC β-lactamase. Structure, 10, 1013-1023 (2002).
15. Fox, J. L. The business of developing antibacterials. Nature Biotech. 24, 1521-1528 (2006).